Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2025, with revenue reaching 2.374 billion yuan, a year-on-year growth of 50.57% [1] - Net profit attributable to shareholders was 1.051 billion yuan, reflecting a year-on-year increase of 60.22% [1] - The company plans to distribute a cash dividend of 4.00 yuan per 10 shares to all shareholders [1] Revenue Growth - The primary driver of revenue growth was the strong sales performance of the core product, Fumetinin tablets, which saw continuous sales expansion during the reporting period [1] Profitability - The net profit excluding non-recurring gains and losses was 905 million yuan, marking a year-on-year growth of 39.92% [1] - Basic earnings per share were reported at 2.34 yuan [1]
艾力斯(688578.SH):上半年净利润10.51亿元,同比增长60.22%